Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alzamend NeuroALZN -1.18%21 Equity-to-Asset is 0.35 as of Apr. 2026, which is 27% below its 10-year median of 0.48. GuruFocus rates ALZN with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 1,414 Biotechnology companies, Alzamend Neuro ranks worse than 75.88% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Alzamend Neuro's Total Stockholders Equity for the quarter that ended in Apr. 2026 was $0.73 Mil. Alzamend Neuro's Total Assets for the quarter that ended in Apr. 2026 was $2.08 Mil.
The historical rank and industry rank for Alzamend Neuro's Equity-to-Asset or its related term are showing as below:
ALZN'
s Equity-to-Asset Range Over the Past 10 Years
Min: -4.1 Med: 0.48 Max: 0.92
Current: 0.35
During the past 8 years, the highest Equity to Asset Ratio of Alzamend Neuro was 0.92. The lowest was -4.10. And the median was 0.48.
ALZN's Equity-to-Asset is ranked worse than 75.88% of 1414
companies
in the Biotechnology industry
Industry Median: 0.68
vs ALZN: 0.35
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Alzamend Neuro Equity-to-Asset Related Terms
Alzamend Neuro Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Alzamend Neuro's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALZN vs CNSP, SNGX, AIM: Equity-to-Asset Comparison
For the Biotechnology subindustry, Alzamend Neuro's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alzamend Neuro Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alzamend Neuro's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Alzamend Neuro's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Alzamend Neuro's Equity to Asset Ratio for the fiscal year that ended in Apr. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alzamend Neuro (ALZN) has a Equity-to-Asset of 0.35 as of Apr. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Alzamend Neuro and its competitors. This is 27% below median its historical median of 0.48. According to the industry distribution chart, Alzamend Neuro ranks #1073 out of 1414 companies in the Biotechnology industry, placing it in the top 75.9%.
Is Alzamend Neuro's Equity-to-Asset too high?
Alzamend Neuro's current Equity-to-Asset of 0.35 is 27% below median its 10-year median of 0.48. The Biotechnology industry median Equity-to-Asset is 0.68. Alzamend Neuro's value of 0.35 is 48.5% below this industry median. Based on the distribution chart, Alzamend Neuro ranks #1073 out of 1414 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alzamend Neuro has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Alzamend Neuro's Equity-to-Asset compare to CNSP and SNGX?
According to the Biotechnology industry distribution chart, Alzamend Neuro ranks #1073 out of 1414 companies for Equity-to-Asset. This places Alzamend Neuro in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Alzamend Neuro's value of 0.35 is 48.5% below this benchmark. While the company's 10-year median is 0.48 vs. the industry median of 0.68, Alzamend Neuro has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alzamend Neuro's current Equity-to-Asset of 0.35 is 48.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Alzamend Neuro and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alzamend Neuro's current Equity-to-Asset is 0.35, which is 27% below median its own 10-year median of 0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alzamend Neuro stock overvalued right now?
Alzamend Neuro (ALZN) has a current Equity-to-Asset of 0.35. The current Equity-to-Asset is 0.35, which is 27% below median its 10-year median of 0.48 and 48.5% below the Biotechnology industry median of 0.68. Alzamend Neuro's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Alzamend Neuro (ALZN), the current Equity-to-Asset is 0.35 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
21GF Score
Get the complete analysis for ALZN
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALZN has been successfully added to your 
